Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity, at the American Diabetes Association meeting in New Orleans.
Save my name, email, and website in this browser for the next time I comment.
Your Name (required)
Your Email (required)
Subject
Your Message
WhatsApp us
